HANGZHOU, China. – 12 October 2020 – Ranok Therapeutics Co. Ltd., a pre-clinical stage, virtual biopharmaceutical company focused on developing therapeutics for cancers and other serious diseases, today announced that it will present this week at the 3rd Annual Targeted Protein Degradation (TPD) Summit.  Previously held annually in Boston MA USA, for 2020 the TPD Summit is being held online (www.proteindegradation.com ).


Kevin P. Foley, Ph.D., Ranok’s Co-founder and Chief Scientific Officer will present during the “Beyond UPS-mediated Degradation Strategies” session at 1:50 PM ET on 15 October 2020. During his talk, which is entitled “Chaperone-mediated Targeted Protein Degradation,” Dr. Foley will describe Ranok’s CHAMPTM technology platform and its application to the development of tumor-targeted, highly selective and potent small molecule protein degraders. Dr. Foley will also be chairing the “Accelerating Discovery & Emerging Strategies” sessions on 14 October 2020.


“We are pleased to participate in the 3rd Annual Targeted Protein Degradation Summit and publicly describe for the first time in the US how Ranok is employing cellular chaperone proteins too mediate degradation of important drug targets in a tumor-selective fashion, “ said Dr. Foley.  “We are also excited to join our peers to discuss the state of the art in the rapidly evolving field of targeted protein degradation and other induced proximity technologies.”


About Ranok Therapeutics


Ranok is a privately held, pre-clinical stage, virtual biopharmaceutical company that is pioneering an innovative targeted protein degradation technology for the discovery and development of novel therapeutics.  Ranok was founded by a leadership team composed of industry veterans from both Chinese and American biotech and pharmaceutical companies and is based in two of the world’s leading centers of innovation and medical research: Hangzhou China and Boston Massachusetts USA. By bringing together the cutting edges of medical research from both China and the United States, our goal is to create transformative medicines for patients suffering from cancer and other serious diseases. For more information, please visit the company website at www.ranoktherapeutics.com or follow us at LinkedIn and on Twitter @RanokTx.




Chaperone-mediated Protein Degradation/Degrader (CHAMPTM) technology is based on our founders’ extensive backgrounds in protein homeostasis research. This technology takes advantage of different underlying biological processes from other targeted protein degradation approaches such as PROTAC, and has a number of unique advantages, including improved safety due to the selective targeting of tumors. Our proprietary R&D engine combines deep biological insight and chemistry expertise to iteratively discover and test new leads, rapidly identifying and advancing optimal development candidates for a variety of important disease targets.



Media & Investor Contact:
Ms. Xiaoyan Qiu
Ranok Therapeutics Co. Ltd.

– First public disclosure of Ranok’s innovative CHAMPTM technology platform at a drug discovery conference in the US

Ranok Therapeutics to Present at the 3rd Annual Targeted Protein Degradation (TPD) Summit